List of Therapeutic Companies in Nevada - 9

We are a clinical stage diagnostics company committed to developing and commercializing novel products for the treatment and management of all cancers.

Ageless Biotech (ABT) is in the development of discardable, minimally manipulated umbilical tissue based regenerative medicine biologics to address all forms of Osteoarthritis via intra-articular procedures in cooperation with leading scientists and medical professionals. Our ambition is to become a leading global biopharmaceutical company, focused on the discovery, development and commercialization of innovative medicines that will improve people's lives. We believe that the formation of life itself is contained within after birth tissues. ABT believes that it is morally, religiously and politically acceptable to use afterbirth materials that would be considered discardable in virtually every country. Furthermore, we believe this to be the right course to addressing problems that a vast majority of the population will face at some point during their lifespan.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer’s disease, as well as Phase 2 clinical trial for the treatment of Parkinson’s disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

CV Sciences produces both pharmaceuticals and consumer products. ThePharmaceutical Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications utilizing cannabidiol as the active pharmaceutical ingredient.CV Sciences’ Consumer Products Division delivers botanical‐based cannabidiol products that enhance quality of life. Currently distributed nationally in health food stores, health care provider’s offices and online, each consumer products brand is backed by a formal safety review, growing body of case reports, and physician’s recommendations.

Heligenics is a life sciences company that has developed proprietary technology, which shows the impact of genetic mutations to revolutionize genetic testing and drug development for major diseases. We are the first company to develop High Content Screening for Biologic Drugs, previously the mainstay for the development of small compound drugs. As the effect of most mutations on gene function is largely unknown, Heligenics comprehensively measures the functional significance of mutations in the human genome through a massively parallel in-vitro process called the GigaAssay, measuring the impact of all potential amino acid substitutions in the functional target protein, doing in a few months what would take many years to do if at all. For cancer diagnostics companies, our functional data enables improved genetic test interpretation, and for pharmaceutical companies, we empower the conversion of generic drugs into targeted precision medicines or can rescue a failed drug candidate through the identification of variants for a redesigned genetically stratified clinical trial. Explore more! Email: mschiller@heligenics.com Website: Heligenics.com LinkedIn: linkedin.com/company/heligenics-inc/ Twitter: twitter.com/heligenics

RosVivo Therapeutics is a biotechnology company that develops microRNA-based therapeutics for type 2 diabetes, obesity, and fatty liver disease. They have signed a Material Transfer Agreement for first-in-class diabetes treatment with Eli Lilly and Company.

A diagnosis of a serious illness can change life in an instant and finding treatment options is key. At Secura Bio®, we see things differently. We develop and commercialize innovative medicines and life changing products for the patients that need them most.

"Zhittya (meaning Life in Ukrainian) is a biotechnology company based in Las Vegas, Nevada. Zhittya is seeking to commercialize human FGF-1, a naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have been working to bring this drug to market. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. There are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues, and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.

Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA.